Ventyx Biosciences Inc. (NASDAQ: VTYX)
$2.85
+0.2900 ( +11.33% ) 929.2K
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Market Data
Open
$2.85
Previous close
$2.56
Volume
929.2K
Market cap
$200.22M
Day range
$2.56 - $2.86
52 week range
$1.87 - $38.20
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jul 13, 2023 |
4 | Insider transactions | 1 | Jul 13, 2023 |
4 | Insider transactions | 1 | Jul 11, 2023 |
4 | Insider transactions | 1 | Jul 11, 2023 |
4 | Insider transactions | 1 | Jul 06, 2023 |
4 | Insider transactions | 1 | Jul 06, 2023 |
4 | Insider transactions | 1 | Jul 05, 2023 |
4 | Insider transactions | 1 | Jul 05, 2023 |
4 | Insider transactions | 1 | Jul 05, 2023 |
4 | Insider transactions | 1 | Jul 05, 2023 |